Schistosomiasis and infection with human immunodeficiency virus 1 in rural Zimbabwe: systemic inflammation during co-infection and after treatment for schistosomiasis.
We previously reported that treatment for schistosomiasis in persons infected with human immunodeficiency virus 1 (HIV-1) attenuated HIV replication as measured by plasma HIV RNA. We investigated systemic inflammation as measured by plasma levels of soluble tumor necrosis factor-alpha receptor II (sTNF-rII), interleukin-8, (IL-8), and IL-10 during schistosomiasis and HIV co-infection and after schistosomiasis treatment. The cohort was composed of 378 persons who were or were not infected with HIV-1, Schistosoma haematobium, or S. mansoni. Schistosomiasis-infected persons were randomized to receive praziquantel (40 mg/kg) at baseline or at the three-month follow-up. sTNF-rII and IL-8 were positively associated with schistosomiasis intensity as measured by circulating anodic antigen (CAA), regardless of HIV status. Interleukin-10 was positively associated with CAA in HIV-negative participants. IL-8 levels were higher in S. mansoni-infected individuals. Treatment for schistosomiasis caused a decrease in levels of sTNF-rII (P < 0.05) and IL-10 (P < 0.001). Our results indicate that schistosomiasis treatment may attenuate HIV replication by decreasing systemic inflammation.
Erikstrup
Christian
C
Department of Clinical Immunology, Aarhus University Hospital, Skejby Sygehus, Aarhus, Denmark. christian@erikstrup.org
Kallestrup
Per
P
Zinyama-Gutsire
Rutendo B L
RB
Gomo
Exnevia
E
van Dam
Govert J
GJ
Deelder
André M
AM
Butterworth
Anthony E
AE
Pedersen
Bente Klarlund
BK
Ostrowski
Sisse R
SR
Gerstoft
Jan
J
Ullum
Henrik
H
D000293:Adolescent; D000328:Adult; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D016207:Cytokines / Q000097:blood; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000150:complications* / Q000453:epidemiology; D015497:HIV-1; D006801:Humans; D007249:Inflammation / Q000209:etiology*; D016753:Interleukin-10 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D008297:Male; D008875:Middle Aged; D011223:Praziquantel / Q000627:therapeutic use; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000097:blood; D012552:Schistosomiasis / Q000097:blood / Q000150:complications* / Q000188:drug therapy* / Q000453:epidemiology; D012556:Schistosomicides / Q000627:therapeutic use*; D015030:Zimbabwe / Q000453:epidemiology
D016207:Cytokines; D016209:Interleukin-8; D047889:Receptors, Tumor Necrosis Factor, Type II; D012556:Schistosomicides; D016753:Interleukin-10; D011223:Praziquantel